Two bornyl derivatives of p-(benzyloxy)phenylpropionic acid 1 and 2 were studied for their ability to normalize glucose metabolism in mice with metabolic disorders (C57BL/6Ay strain, AY). Compounds were tested at dose of 30 mg/kg. Vildagliptin (VIL) was used as a positive control in the same dose. Glucose tolerance test (OGTT) immediately performed after the first oral introduction of studied compounds to AY mice did not show a hypoglycemic effect but revealed the impaired glucose tolerance in untreated mice. Conversely administration of 1 exerted a hyperglycemic effect. After 14 days of administration, another OGTT was carried out, where it was found that glucose tolerance in untreated AY mice remained abnormal. At the same time, a significant hypoglycemic effect was detected in mice treated by 2. The hyperglycemic effect of 1 decreased, but the total glucose level in these animals did not differ from that in the untreated AY group. The administration of VIL for 2 weeks also improved the results of the OGTT. During histological examination of the mice liver at the end of the experiment, it was found that in animals having received 1 for 14 days, there was alleviation of metabolic disturbances whereas is those who received 2, partial correction of the metabolic abnormalities was detected. In VIL group no correction of metabolic abnormalities was found. These differences suggest different mechanism of action of VIL and studied compounds. Thus, the results obtained indicate that 1 and 2 have a good potential as new agents for diabetes mellitus treatment.